Cholinesterase mediated metabolism. No data pointing to CYP-inducing properties.
Chemical description
Carbamate type of cholinesterase inhibitor used in light to moderate Alzheimer´s disease. Rapidly (t/2 60 minutes)´metabolized by cholinesterase mediated hydrolysis to the decarbamylated metabolite. CYP-metabolism probably of small importance. No data pointing to CYP-induction or inhibition.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
Similar drugs
Explore alternative drugs in similar therapeutic classes
N06D /
N06DA or
go back.